Evidence map›Paper›PMID 22180633›Full record

Trial reportJournal of lipid research2012

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.

Ronald M Krauss, Kathleen Wojnooski, Joseph Orr, J Casey Geaney, Cathy Anne Pinto, Yang Liu, John A Wagner, Julie Mabalot Luk, Amy O Johnson-Levonas, Matt S Anderson and 1 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of lipid research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Lipid Dysregulation in Tangier Disease: A Case Series and Metabolic Characterization.The Journal of clinical endocrinology and metabolism · 2025
    Article
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Ronald M KraussChildren's Hospital Oakland Research Institute, Oakland, CA; and. Electronic address: rkrauss@chori.org.
Kathleen WojnooskiChildren's Hospital Oakland Research Institute, Oakland, CA; and.
Joseph OrrChildren's Hospital Oakland Research Institute, Oakland, CA; and.
J Casey GeaneyChildren's Hospital Oakland Research Institute, Oakland, CA; and.
Cathy Anne PintoMerck Sharp & Dohme Corp., Whitehouse Station, NJ.
Yang LiuMerck Sharp & Dohme Corp., Whitehouse Station, NJ.
John A WagnerMerck Sharp & Dohme Corp., Whitehouse Station, NJ.
Julie Mabalot LukMerck Sharp & Dohme Corp., Whitehouse Station, NJ.
Amy O Johnson-LevonasMerck Sharp & Dohme Corp., Whitehouse Station, NJ.
Matt S AndersonMerck Sharp & Dohme Corp., Whitehouse Station, NJ.
Hayes M DanskyMerck Sharp & Dohme Corp., Whitehouse Station, NJ.
Merck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the effects of the cholesteryl ester (CE) transfer protein inhibitor anacetrapib (ANA) on plasma lipids, lipoprotein subfraction concentrations, and lipoprotein composition in 30 healthy individuals. Participants (n = 30) were randomized to ANA 20 mg/day, 150 mg/day, or placebo for 2 weeks. Changes in concentration of lipoprotein subfractions were assessed using ion mobility, and compositional analyses were performed on fractions separated by density gradient ultracentrifugation. ANA 150 mg/day versus placebo resulted in significant decreases in LDL-cholesterol (26%) and apo B (29%) and increases in HDL-cholesterol (82%). Concentrations of medium and small VLDL, large intermediate density lipoprotein (IDL), and medium and small LDL (LDL2a, 2b, and 3a) decreased whereas levels of very small and dense LDL4b were increased. There was enrichment of triglycerides and reduction of CE in VLDL, IDL, and the densest LDL fraction. Levels of large buoyant HDL particles were substantially increased, and there was enrichment of CE, apo AI, and apoCIII, but not apoAII or apoE, in the mid-HDL density range. Changes in lipoprotein subfraction concentrations and composition with ANA 20 mg/day were similar to those for ANA 150 mg/day but were generally smaller in magnitude. The impact of these changes on cardiovascular risk remains to be determined.

Indexed as

AdolescentAdultApolipoprotein A-IApolipoproteins BCholesterol Ester Transfer ProteinsCholesterol, HDLCholesterol, VLDLFemaleHumansLipid MetabolismLipidsLipoproteinsLipoproteins, HDLLipoproteins, LDLMaleMiddle AgedanacetrapibApolipoprotein A-IApolipoproteins BCETP protein, humanCholesterol Ester Transfer ProteinsCholesterol, HDLCholesterol, VLDLLipidsLipoproteinsLipoproteins, HDLLipoproteins, LDLOxazolidinones

Identifiers

PMID22180633
PMCPMC3276477
OpenAlexW2104650041

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.